{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:27:31Z","timestamp":1787923651659,"version":"build-2784847793"},"reference-count":32,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Pediatric inflammatory bowel disease (IBD) incidence is rising among racial and ethnic minority children, yet to our knowledge no comprehensive evaluation of demographic representation in pediatric IBD trials exists. We systematically evaluated the reporting and representation of race, ethnicity, and sex in pediatric IBD clinical trials, stratified by Crohn disease (CD) and ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a cross-sectional study of pediatric IBD trials identified in PubMed and EMBASE through March 2026. Reference distributions were derived from the National Patient-Centered Clinical Research Network (race\/ethnicity, United States) and the Global Burden of Disease Study 2023 (sex, global). Enrollment incidence ratios (EIRs) were used to compare trial enrollment to expected disease burden. Comparisons were performed with random-effects meta-analyses that pooled trial-level estimates, with subgroup analyses, sensitivity analyses, and meta-regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 145 trials enrolling 8273 children, sex and race were consistently reported; ethnicity reporting rose from 0% before 2000 to 87.5% after 2020. Female participants were underrepresented (EIR, 0.91; 95% CI, 0.87-0.95), most markedly in CD trials (EIR, 0.82; 95% CI, 0.78-0.88). Black (EIR, 0.55; 95% CI, 0.42-0.71) and Hispanic (EIR, 0.46; 95% CI, 0.28-0.76) participants were underrepresented. Asian\/Pacific Islander participants were overrepresented (EIR, 1.78; 95% CI, 1.37-2.30), while White and non-Hispanic participants were proportionally represented. Meta-regression showed gains over time for Asian\/Pacific Islander, female, and Hispanic participants, but a slight decline for Black participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Female and Black children remain persistently underrepresented in pediatric IBD trials relative to disease burden; findings for Hispanic children were similar but based on a small number of trials. Enforceable diversity action plans and standardized demographic reporting are urgently needed to ensure equitable therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag169","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:47:10Z","timestamp":1785498430000},"source":"Crossref","is-referenced-by-count":0,"title":["Reporting and representation of participant race, ethnicity, and sex in pediatric IBD clinical trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-2498","authenticated-orcid":false,"given":"Yunlin","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingye","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University , Nanjing, Jiangsu,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Proctology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082801031891600_izag169-B1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","article-title":"GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"key":"2026082801031891600_izag169-B2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2026082801031891600_izag169-B3","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.3748\/wjg.v24.i25.2741","article-title":"Current global trends in the incidence of pediatric-onset inflammatory bowel disease","volume":"24","author":"S\u00fdkora","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026082801031891600_izag169-B4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ajg.2017.97","article-title":"Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases","volume":"112","author":"Benchimol","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2026082801031891600_izag169-B5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.crohns.2013.09.001","article-title":"National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States","volume":"8","author":"Nguyen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026082801031891600_izag169-B6","doi-asserted-by":"publisher","first-page":"1756284819827692","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"2026082801031891600_izag169-B7","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2026082801031891600_izag169-B8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology"},{"key":"2026082801031891600_izag169-B9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.cgh.2008.07.032","article-title":"Inflammatory bowel disease in African American children compared with other racial\/ethnic groups in a multicenter registry","volume":"6","author":"White","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082801031891600_izag169-B10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/01.mib.0000171279.05471.21","article-title":"Comparative phenotypic and CARD15 mutational analysis among African American, Hispanic, and White children with Crohn\u2019s disease","volume":"11","author":"Kugathasan","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031891600_izag169-B11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/MIB.0000000000000325","article-title":"Racial disparities in readmission, complications, and procedures in children with Crohn\u2019s disease","volume":"21","author":"Dotson","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031891600_izag169-B12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2018.06.043","article-title":"Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from western countries","volume":"155","author":"Shah","year":"2018","journal-title":"Gastroenterology"},{"key":"2026082801031891600_izag169-B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000504701","article-title":"Gender differences in inflammatory bowel disease","volume":"101 Suppl 1","author":"Greuter","year":"2020","journal-title":"Digestion"},{"key":"2026082801031891600_izag169-B14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","article-title":"Racial and ethnic disparities in adverse drug events: a systematic review of the literature","volume":"2","author":"Baehr","year":"2015","journal-title":"J Racial Ethn Health Disparities"},{"key":"2026082801031891600_izag169-B15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"2026082801031891600_izag169-B16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cgh.2023.07.026","article-title":"Geographic inequities in access to Phase 3 clinical trials for inflammatory bowel disease in the United States","volume":"22","author":"Boyd","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082801031891600_izag169-B17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026082801031891600_izag169-B18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/ibd\/izab219","article-title":"Racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"28","author":"Barnes","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031891600_izag169-B19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2020.09.036","article-title":"PCORnet\u00ae 2020: current state, accomplishments, and future directions","volume":"129","author":"Forrest","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2026082801031891600_izag169-B20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ecco-jcc\/jjad138","article-title":"Race and ethnic representation in Crohn\u2019s disease trials of biologic and small molecule medications: a systematic review and meta-analysis","volume":"18","author":"Pelton","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026082801031891600_izag169-B21"},{"key":"2026082801031891600_izag169-B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-026-02800-7","article-title":"Racial, ethnic, gender and age representation of clinical trials supporting FDA approval of cancer therapies","volume":"25","author":"Zhao","year":"2026","journal-title":"Int J Equity Health"},{"key":"2026082801031891600_izag169-B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.gastro.2020.08.064","article-title":"Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases","volume":"160","author":"Barnes","year":"2021","journal-title":"Gastroenterology"},{"key":"2026082801031891600_izag169-B24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ibd.22986","article-title":"Systematic review: the role of race and socioeconomic factors on IBD healthcare delivery and effectiveness","volume":"19","author":"Sewell","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2026082801031891600_izag169-B25","volume-title":"Diversity Action Plans to Improve Enrollment of Participants From Underrepresented Populations in Clinical Studies: Draft Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"2026082801031891600_izag169-B26","author":"National Academies of Sciences EAM, Global PA, Affairs","year":"2022"},{"key":"2026082801031891600_izag169-B27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026082801031891600_izag169-B28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","article-title":"NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity","volume":"48","author":"Moriyama","year":"2016","journal-title":"Nat Genet"},{"key":"2026082801031891600_izag169-B29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"2026082801031891600_izag169-B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"2026082801031891600_izag169-B31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2288-14-42","article-title":"Reaching the hard-to-reach: a systematic review of strategies for improving health and medical research with socially disadvantaged groups","volume":"14","author":"Bonevski","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026082801031891600_izag169-B32","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jacbts.2021.01.011","article-title":"Decentralized clinical trials: the future of medical product development?","volume":"6","author":"Van Norman","year":"2021","journal-title":"JACC Basic Transl Sci"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag169\/70823132\/izag169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izag169\/70823132\/izag169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:44:09Z","timestamp":1787921049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izag169\/8772151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag169","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"izag169"}}